PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
61.53%
Cash & equivalents growing 61.53% while TRVN's declined -59.75%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
61.53%
Cash + STI yoy ≥ 1.5x TRVN's 1.77%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.75%
≥ 1.5x TRVN's 2.83%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
529.47%
Below half TRVN's -3.52%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
588.21%
Below half of TRVN's -11.30%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
63.35%
≥ 1.5x TRVN's 0.60%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
9.62%
50-75% of TRVN's 12.92%. Bruce Berkowitz notes the company is paying suppliers faster or not stretching terms as competitor does.
59.49%
Above 1.5x TRVN's 2.94%. Michael Burry sees a major discrepancy in short-term leverage. Check coverage and liquidity carefully.
No Data
No Data available this quarter, please select a different quarter.
103.88%
Higher Deferred Revenue (Current) Growth compared to TRVN's zero value, indicating better performance.
-531.94%
Exceeding 1.5x TRVN's -2.94%. Michael Burry suspects ballooning short-term obligations vs. competitor.
9.77%
1.25-1.5x TRVN's 6.53%. Martin Whitman is wary of bigger short-term burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1866750.00%
Above 1.5x TRVN's 217.44%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
661.90%
Above 1.5x TRVN's 92.12%. Michael Burry sees a potential leverage warning sign.
13.64%
Higher Common Stock (Book Value) Growth compared to TRVN's zero value, indicating worse performance.
-2.98%
Similar yoy to TRVN's -2.93%. Walter Schloss sees parallel earnings retention vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.57%
Below half TRVN's -27.24%. Michael Burry sees potential underperformance in building shareholder capital.
63.35%
≥ 1.5x TRVN's 0.60%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
1244.16%
Above 1.5x TRVN's 192.14%. Michael Burry sees a major jump. Investigate leverage rationale.
-58.28%
Less than half of TRVN's 101.44%. David Dodd sees better deleveraging or stronger cash buildup than competitor.